{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:18:39Z","timestamp":1792523919415,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82525064, 82273876"],"award-info":[{"award-number":["82525064, 82273876"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271521"],"award-info":[{"award-number":["82271521"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20240012"],"award-info":[{"award-number":["BK20240012"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004806","name":"Fok Ying Tong Education Foundation","doi-asserted-by":"publisher","award":["171028"],"award-info":[{"award-number":["171028"]}],"id":[{"id":"10.13039\/501100004806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41565-026-02194-1","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:05:49Z","timestamp":1784797549000},"page":"1203-1214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunostimulatory lipogel implant enhances cancer immunotherapy"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1124-1043","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enlai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanlin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1532-7582","authenticated-orcid":false,"given":"Mingqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-4456","authenticated-orcid":false,"given":"Zhen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4010-8879","authenticated-orcid":false,"given":"Ran","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2194_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7807","volume":"10","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & Lopez-Soto, A. The hallmarks of successful anticancer immunotherapy. Sci. Transl. Med. 10, eaat7807 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2194_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2194_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002\u20131014 (2021).","journal-title":"Lancet"},{"key":"2194_CR4","first-page":"505","volume":"70","author":"JW Carlisle","year":"2020","unstructured":"Carlisle, J. W., Steuer, C. E., Owonikoko, T. K. & Saba, N. F. An update on the immune landscape in lung and head and neck cancers. CA Cancer J. Clin. 70, 505\u2013517 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"2194_CR5","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/annonc\/mdx151","volume":"28","author":"MB Atkins","year":"2017","unstructured":"Atkins, M. B., Clark, J. I. & Quinn, D. I. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann. Oncol. 28, 1484\u20131494 (2017).","journal-title":"Ann. Oncol."},{"key":"2194_CR6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"2194_CR7","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"2194_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2194_CR9","doi-asserted-by":"publisher","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2194_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","volume":"120","author":"L Hirsch","year":"2019","unstructured":"Hirsch, L., Zitvogel, L., Eggermont, A. & Marabelle, A. PD-Loma: a cancer entity with a shared sensitivity to the PD-1\/PD-L1 pathway blockade. Br. J. Cancer 120, 3\u20135 (2019).","journal-title":"Br. J. Cancer"},{"key":"2194_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2194_CR12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920\u2013928 (2019).","journal-title":"Nat. Med."},{"key":"2194_CR13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22, 1034\u20131046 (2021).","journal-title":"Lancet Oncol."},{"key":"2194_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"2194_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).","journal-title":"Cell Death Dis."},{"key":"2194_CR16","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2194_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2194_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","volume":"27","author":"I Vitale","year":"2021","unstructured":"Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 27, 212\u2013224 (2021).","journal-title":"Nat. Med."},{"key":"2194_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"2194_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"JJ Loh","year":"2024","unstructured":"Loh, J. J. & Ma, S. Hallmarks of cancer stemness. Cell Stem Cell 31, 617\u2013639 (2024).","journal-title":"Cell Stem Cell"},{"key":"2194_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-021-00366-w","volume":"21","author":"D Bayik","year":"2021","unstructured":"Bayik, D. & Lathia, J. D. Cancer stem cell\u2013immune cell crosstalk in tumour progression. Nat. Rev. Cancer 21, 526\u2013536 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2194_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","volume":"18","author":"NK Lytle","year":"2018","unstructured":"Lytle, N. K., Barber, A. G. & Reya, T. Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer 18, 669\u2013680 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2194_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/0008-5472.CAN-09-1592","volume":"70","author":"T Schatton","year":"2010","unstructured":"Schatton, T. et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 70, 697\u2013708 (2010).","journal-title":"Cancer Res."},{"key":"2194_CR24","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1038\/s41388-019-0700-2","volume":"38","author":"L Castagnoli","year":"2019","unstructured":"Castagnoli, L. et al. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. Oncogene 38, 4047\u20134060 (2019).","journal-title":"Oncogene"},{"key":"2194_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04313-6","volume":"9","author":"JM Hsu","year":"2018","unstructured":"Hsu, J. M. et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat. Commun. 9, 1908 (2018).","journal-title":"Nat. Commun."},{"key":"2194_CR26","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.cell.2019.03.025","volume":"177","author":"Y Miao","year":"2019","unstructured":"Miao, Y. et al. Adaptive immune resistance emerges from tumor-initiating stem cells. Cell 177, 1172\u20131186.e14 (2019).","journal-title":"Cell"},{"key":"2194_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay1813","volume":"369","author":"S Taniguchi","year":"2020","unstructured":"Taniguchi, S. et al. Tumor-initiating cells establish an IL-33-TGF-\u03b2 niche signaling loop to promote cancer progression. Science 369, eaay1813 (2020).","journal-title":"Science"},{"key":"2194_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck, R., Turley, S. J. & Akhurst, R. J. TGF\u03b2 biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2194_CR29","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1158\/0008-5472.CAN-14-3590","volume":"75","author":"Q Zhang","year":"2015","unstructured":"Zhang, Q. et al. CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast cancer. Cancer Res. 75, 4312\u20134321 (2015).","journal-title":"Cancer Res."},{"key":"2194_CR30","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1158\/0008-5472.CAN-21-1337","volume":"81","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. Cancer Res. 81, 5919\u20135934 (2021).","journal-title":"Cancer Res."},{"key":"2194_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16789-2","volume":"11","author":"J Yin","year":"2020","unstructured":"Yin, J. et al. ARS2\/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. Nat. Commun. 11, 2978 (2020).","journal-title":"Nat. Commun."},{"key":"2194_CR32","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1158\/0008-5472.CAN-18-2659","volume":"79","author":"C Shidal","year":"2019","unstructured":"Shidal, C., Singh, N. P., Nagarkatti, P. & Nagarkatti, M. MicroRNA-92 expression in CD133+ melanoma stem cells regulates immunosuppression in the tumor microenvironment via integrin-dependent activation of TGF\u03b2. Cancer Res. 79, 3622\u20133635 (2019).","journal-title":"Cancer Res."},{"key":"2194_CR33","doi-asserted-by":"publisher","first-page":"108597","DOI":"10.1016\/j.celrep.2020.108597","volume":"34","author":"P Chen","year":"2021","unstructured":"Chen, P., Hsu, W. H., Han, J., Xia, Y. & DePinho, R. A. Cancer stemness meets immunity: from mechanism to therapy. Cell Rep. 34, 108597 (2021).","journal-title":"Cell Rep."},{"key":"2194_CR34","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41590-022-01293-0","volume":"23","author":"L Galluzzi","year":"2022","unstructured":"Galluzzi, L. & Kroemer, G. Immuno-epigenetic escape of cancer stem cells. Nat. Immunol. 23, 1300\u20131302 (2022).","journal-title":"Nat. Immunol."},{"key":"2194_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.tips.2022.03.004","volume":"44","author":"G Blanco-Fernandez","year":"2022","unstructured":"Blanco-Fernandez, G., Blanco-Fernandez, B., Fern\u00e1ndez-Ferreiro, A. & Otero-Espinar, F. Bringing lipidic lyotropic liquid crystal technology into biomedicine. Trends Pharmacol. Sci. 44, 7\u201310 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"2194_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/DDDT.S103505","volume":"11","author":"R Rajabalaya","year":"2017","unstructured":"Rajabalaya, R., Musa, M. N., Kifli, N. & David, S. R. Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals. Drug Des. Devel. Ther. 11, 393\u2013406 (2017).","journal-title":"Drug Des. Devel. Ther."},{"key":"2194_CR37","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang, Z. Y. & Chen, Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111, 2505\u20132515 (2008).","journal-title":"Blood"},{"key":"2194_CR38","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1038\/onc.2016.87","volume":"35","author":"PH Nguyen","year":"2016","unstructured":"Nguyen, P. H. et al. All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth. Oncogene 35, 5619\u20135628 (2016).","journal-title":"Oncogene"},{"key":"2194_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06818-0","volume":"20","author":"W Yao","year":"2020","unstructured":"Yao, W. et al. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells. BMC Cancer 20, 315 (2020).","journal-title":"BMC Cancer"},{"key":"2194_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jconrel.2010.10.019","volume":"149","author":"RJ Li","year":"2011","unstructured":"Li, R. J. et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J. Control. Release 149, 281\u2013291 (2011).","journal-title":"J. Control. Release"},{"key":"2194_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.biomaterials.2014.10.018","volume":"37","author":"R Sun","year":"2015","unstructured":"Sun, R. et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials 37, 405\u2013414 (2015).","journal-title":"Biomaterials"},{"key":"2194_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41565-020-00793-0","volume":"16","author":"S Shen","year":"2021","unstructured":"Shen, S. et al. A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nat. Nanotechnol. 16, 104\u2013113 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"2194_CR43","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/stem.1193","volume":"30","author":"Y Luo","year":"2012","unstructured":"Luo, Y. et al. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30, 2100\u20132113 (2012).","journal-title":"Stem Cells"},{"key":"2194_CR44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature06489","volume":"451","author":"T Schatton","year":"2008","unstructured":"Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345\u2013349 (2008).","journal-title":"Nature"},{"key":"2194_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361 (2007).","journal-title":"Nat. Med."},{"key":"2194_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41427-019-0134-x","volume":"11","author":"LM Mu","year":"2019","unstructured":"Mu, L. M. et al. Development of functional dendrisomes based on a single molecule of polyesterbenzylether dendrimer and their application in cancer stem cell therapy. NPG Asia Mater. 11, 34 (2019).","journal-title":"NPG Asia Mater."},{"key":"2194_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.gene.2016.07.052","volume":"592","author":"XY Chen","year":"2016","unstructured":"Chen, X. Y. et al. Differentiation-inducing and anti-proliferative activities of isoliquiritigenin and all-trans-retinoic acid on B16F0 melanoma cells: mechanisms profiling by RNA-seq. Gene 592, 86\u201398 (2016).","journal-title":"Gene"},{"key":"2194_CR48","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1080\/17425247.2020.1819979","volume":"17","author":"AVP Silvestrini","year":"2020","unstructured":"Silvestrini, A. V. P., Caron, A. L., Viegas, J., Pra\u00e7a, F. G. & Bentley, M. Advances in lyotropic liquid crystal systems for skin drug delivery. Expert Opin. Drug Deliv. 17, 1781\u20131805 (2020).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2194_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.actbio.2019.09.011","volume":"99","author":"B Wang","year":"2019","unstructured":"Wang, B. et al. Self-assembling in situ gel based on lyotropic liquid crystals containing VEGF for tissue regeneration. Acta Biomater. 99, 84\u201399 (2019).","journal-title":"Acta Biomater."},{"key":"2194_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","volume":"14","author":"Q Chen","year":"2019","unstructured":"Chen, Q. et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat. Nanotechnol. 14, 89\u201397 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"2194_CR51","doi-asserted-by":"publisher","first-page":"eaan3682","DOI":"10.1126\/scitranslmed.aan3682","volume":"10","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. In situ formed reactive oxygen species\u2013responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci. Transl. Med. 10, eaan3682 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2194_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04261-y","volume":"12","author":"G Jiang","year":"2021","unstructured":"Jiang, G. et al. Single-cell transcriptomics reveal the heterogeneity and dynamic of cancer stem-like cells during breast tumor progression. Cell Death Dis. 12, 979 (2021).","journal-title":"Cell Death Dis."},{"key":"2194_CR53","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41388-020-01560-0","volume":"40","author":"S Attalla","year":"2021","unstructured":"Attalla, S., Taifour, T., Bui, T. & Muller, W. Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo. Oncogene 40, 475\u2013491 (2021).","journal-title":"Oncogene"},{"key":"2194_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz4204","volume":"6","author":"Y Chao","year":"2020","unstructured":"Chao, Y. et al. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci. Adv. 6, eaaz4204 (2020).","journal-title":"Sci. Adv."},{"key":"2194_CR55","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"MR Lofwall","year":"2018","unstructured":"Lofwall, M. R. et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern. Med. 178, 764\u2013773 (2018).","journal-title":"JAMA Intern. Med."},{"key":"2194_CR56","doi-asserted-by":"publisher","first-page":"617392","DOI":"10.3389\/fonc.2021.617392","volume":"11","author":"J Wei","year":"2021","unstructured":"Wei, J. et al. A bioadhesive barrier-forming oral liquid gel improved oral mucositis and nutritional status in patients with head and neck cancers undergoing radiotherapy: a retrospective single center study. Front. Oncol. 11, 617392 (2021).","journal-title":"Front. Oncol."},{"key":"2194_CR57","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1021\/mp400552u","volume":"11","author":"J Barauskas","year":"2014","unstructured":"Barauskas, J. et al. Bioadhesive lipid compositions: self-assembly structures, functionality, and medical applications. Mol. Pharm. 11, 895\u2013903 (2014).","journal-title":"Mol. Pharm."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41565-026-02194-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-026-02194-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-026-02194-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:02:30Z","timestamp":1786543350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-026-02194-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2194"],"URL":"https:\/\/doi.org\/10.1038\/s41565-026-02194-1","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.M., Y.Z. and E.W. are applying for a patent related to this work. Z.G. is the co-founder of Zenomics Inc., Zencapsule Inc., Lizen Inc., Wskin Inc., ZCapsule Inc. and \u03bcZen Pharma Co., Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}